drugset / Trial / NCT00744276

A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease

NCT00744276

Phase 2 Completed 60 enrolled FemmePharma Global Healthcare, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety of three doses of topically applied danazol compared to placebo in subjects with pain associated with fibrocystic breast disease and to determine the appropriate clinical dose for future studies.

Timeline

Start
2007-01
Primary completion
2009-04
Completion
2009-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Danazol Other / unclassified Topical